Retrospective evaluation of the outcomes of children with diffuse intrinsic pontine glioma treated with radiochemotherapy and valproic acid in a single center

作者: Francisco Helder Cavalcante Felix , Orlandira Leite de Araujo , Karine Martins da Trindade , Nadia Mendonça Trompieri , Juvenia Bezerra Fontenele

DOI: 10.1007/S11060-013-1280-6

关键词:

摘要: Diffuse intrinsic pontine glioma is a pediatric oncologic disease with dismal prognosis and no effective treatment. Since 2007, our patients have been using valproic acid as prophylactic anticonvulsant. We undertaken retrospective study in order to evaluate the influence of valproate outcomes children this center. Patients were treated weekly carboplatin vincristine received conformal radiotherapy, either concurrent or sequential. Event-free survival overall not 6.5 7.8 months. Accelerated failure time model (a parametric multivariate regression test for time-to-failure data) showed statistically significant superiority median event-free (6.5 vs. 9.5 months patients; HR 0.54–95 % CI 0.33–0.87; p < 0.05) also (7.8 13.4 0.60–95 0.37–0.98; = 0.05).

参考文章(30)
Greg D. Guthrie, Sam Eljamel, Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme Journal of Neurosurgery. ,vol. 118, pp. 859- 865 ,(2013) , 10.3171/2012.10.JNS12169
Ivo W Tremont-Lukats, Bernardo O Ratilal, Terri Armstrong, Mark R Gilbert, Antiepileptic drugs for preventing seizures in people with brain tumors Cochrane Database of Systematic Reviews. ,(2008) , 10.1002/14651858.CD004424.PUB2
R J Packer, B Lange, J Ater, H S Nicholson, J Allen, R Walker, M Prados, R Jakacki, G Reaman, M N Needles, Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood Journal of Clinical Oncology. ,vol. 11, pp. 850- 856 ,(1993) , 10.1200/JCO.1993.11.5.850
R. Derek T. Jenkin, Carl Boesel, Inta Ertel, Audrey Evans, Robert Hittle, Jorge Ortega, Richard Sposto, William Wara, Charles Wilson, James Anderson, Sanford Leikin, G. Denman Hammond, Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. Journal of Neurosurgery. ,vol. 66, pp. 227- 233 ,(1987) , 10.3171/JNS.1987.66.2.0227
H S Friedman, J P Krischer, P Burger, W J Oakes, B Hockenberger, M D Weiner, J M Falletta, D Norris, A H Ragab, D H Mahoney, Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. Journal of Clinical Oncology. ,vol. 10, pp. 249- 256 ,(1992) , 10.1200/JCO.1992.10.2.249
D R Macdonald, T L Cascino, S C Schold, J G Cairncross, Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology. ,vol. 8, pp. 1277- 1280 ,(1990) , 10.1200/JCO.1990.8.7.1277
Stefan Oberndorfer, Maria Piribauer, Christine Marosi, Heinz Lahrmann, Peter Hitzenberger, Wolfgang Grisold, P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. Journal of Neuro-oncology. ,vol. 72, pp. 255- 260 ,(2005) , 10.1007/S11060-004-2338-2
Alfonso Duenas-Gonzalez, Myrna Candelaria, Carlos Perez-Plascencia, Enrique Perez-Cardenas, Erick de la Cruz-Hernandez, Luis A. Herrera, Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors Cancer Treatment Reviews. ,vol. 34, pp. 206- 222 ,(2008) , 10.1016/J.CTRV.2007.11.003
A.A. Brandes, E. Franceschi, T. Gorlia, W. Wick, A.H. Jacobs, B.G. Baumert, M. van den Bent, M. Weller, R. Stupp, Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma European Journal of Cancer. ,vol. 48, pp. 896- 903 ,(2012) , 10.1016/J.EJCA.2011.10.027
Darren Hargrave, Nathaniel Chuang, Eric Bouffet, Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma Journal of Neuro-Oncology. ,vol. 86, pp. 313- 319 ,(2008) , 10.1007/S11060-007-9473-5